Bafna Pharma.

Why is Bafna Pharmaceuticals Ltd falling/rising?

As of 09-Aug, Bafna Pharmaceuticals Ltd's stock price has risen to 290.20, reflecting a 1.99% increase. This growth is driven by strong performance metrics, including significant gains over various time frames and achieving new highs, despite a decline in investor participation.

As of 09-Aug, Bafna Pharmaceuticals Ltd is experiencing a rise in its stock price, currently at 290.20, which reflects an increase of 5.65 or 1.99%. This upward movement can be attributed to several factors. The stock has shown impressive performance over various time frames, with a 1-week increase of 8.36%, a 1-month increase of 36.98%, and a year-to-date rise of 86.98%. Additionally, the stock has achieved a new 52-week and all-time high today, indicating strong investor confidence.<BR><BR>Bafna Pharmaceuticals has also outperformed its sector by 1.87% today and has been on a consecutive gain streak for the last 14 days, accumulating a total return of 26.72% during this period. Furthermore, the stock is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which typically signals a bullish trend.<BR><BR>However, it is important to note that there has been a decline in investor participation, with delivery volume falling by 46.39% compared to the 5-day average. Despite this decrease in participation, the overall positive performance metrics and the stock's ability to reach new highs contribute to the current rise in its price.

Which are the latest news on Bafna Pharma.?

When is the next results date for Bafna Pharmaceuticals Ltd?

The next results date for Bafna Pharmaceuticals Ltd is 11 August 2026.

The next results date for Bafna Pharmaceuticals Ltd is scheduled for 11 August 2026.

What does Bafna Pharma. do?

Bafna Pharmaceuticals Ltd manufactures pharmaceutical formulations, focusing on Betalactum and Non Betalactum products. Established in 1981, it reported net sales of 42 Cr and a net profit of 3 Cr for the quarter ending March 2026, with a market cap of INR 398 Cr.

Overview:<BR>Bafna Pharmaceuticals Ltd is engaged in the manufacturing of pharmaceutical formulations, specifically Betalactum and Non Betalactum products, and operates within the Pharmaceuticals & Biotechnology industry as a micro-cap company.<BR><BR>History:<BR>Bafna Pharmaceuticals Ltd was incorporated in 1981 as a proprietary concern by Mr. Bafna Mahaveer Chand. The company established its first manufacturing unit in Madhavaram, Chennai, in October 1984. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 42 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 3 Cr (Quarterly Results - Mar 2026)<BR>- Market Cap: INR 398 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 36.00<BR>- Industry P/E: 34<BR>- Dividend Yield: 0.00%<BR>- Debt-Equity: 0.29<BR>- Return on Equity: 13.09%<BR>- Price to Book: 4.94<BR><BR>Contact Details:<BR>Address: Bafna Towers New No 68, Old No 299 Thambu Chetty St Chennai Tamil Nadu : 600001<BR>Tel: 91-44-25267517/25270992/4267755<BR>Email: info@bafnapharma.com<BR>Website: http://www.bafnapharma.com

How big is Bafna Pharma.?

As of 10th June, Bafna Pharmaceuticals Ltd has a market capitalization of 398.00 Cr and reported net sales of 27.26 Cr with a net loss of 4.00 Cr over the latest three quarters. Shareholder's funds are valued at 51.11 Cr, and total assets amount to 71.31 Cr.

As of 10th June, Bafna Pharmaceuticals Ltd has a market capitalization of 398.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest quarterly performance, the sum of Net Sales for the latest three quarters is 27.26 Cr. The sum of Net Profit for the same period reflects a loss of 4.00 Cr.<BR><BR>The reporting period for the balance sheet is March 2020. Shareholder's Funds are valued at 51.11 Cr, while Total Assets amount to 71.31 Cr.

Who are in the management team of Bafna Pharma.?

The management team of Bafna Pharma includes Chairperson Shanmugam Hemalatha, several Non-Executive Directors, and key roles such as Company Secretaries Roopa Ravikumar and Vishnu Vasudeva Kuppa, along with Whole Time Director Vinayak Dinesh Dendukuri. This team oversees the company's governance and operations.

The management team of Bafna Pharma includes the following individuals:<BR><BR>1. **Shanmugam Hemalatha** - Chairperson / Executive Director<BR>2. **Babulal Kamlesh Kumar** - Non-Executive & Independent Director<BR>3. **Akilapriya Chandrashekar Raju** - Non-Executive & Non-Independent Director<BR>4. **Palamadai Krishnan Sundaresan** - Non-Executive & Independent Director<BR>5. **Ravichandran Chitra** - Non-Executive & Independent Director<BR>6. **Atul Sachdeva** - Non-Executive & Non-Independent Director<BR>7. **Roopa Ravikumar** - Company Secretary<BR>8. **Vishnu Vasudeva Kuppa** - Company Secretary & Compliance Officer<BR>9. **Upendar Mekala Reddy** - Additional Non-Independent Director<BR>10. **Krishna Yeachuri** - Additional Non-Executive & Independent Director<BR>11. **Vinayak Dinesh Dendukuri** - Whole Time Director (Operations)<BR>12. **Upendar Mekala Reddy** - Additional Director<BR>13. **Krishna Yeachuri** - Additional Director<BR><BR>This team plays a crucial role in the governance and operational management of the company.

Who are the peers of the Bafna Pharma.?

Bafna Pharma's peers include Amanta Healthcare, Jenburkt Pharma, Haleos Labs, CCME Global, Albert David, Valiant Laboratories, Medico Remedies, Transchem, and Influx Health. Bafna Pharma has below-average management risk and growth, with a 1-year return of 135.40%, outperforming most peers.

Peers: The peers of Bafna Pharma. are Amanta Healthcar, Jenburkt Pharma, Haleos Labs Limi, CCME Global, Albert David, Valiant Laborato, Medico Remedies, Transchem, and Influx Health.<BR><BR>Quality Snapshot: Excellent management risk is observed at Jenburkt Pharma and Medico Remedies, while Average management risk is found at Amanta Healthcar, Haleos Labs Limi, Albert David, Transchem, and Influx Health. Below Average management risk is present at Bafna Pharma, CCME Global, Valiant Laborato. For growth, Good growth is seen at Valiant Laborato and Influx Health, while Below Average growth is noted at Amanta Healthcar, Jenburkt Pharma, Bafna Pharma, Haleos Labs Limi, CCME Global, Albert David, Medico Remedies, and Transchem. Capital Structure ratings show Excellent at Jenburkt Pharma and Albert David, Good at Bafna Pharma, CCME Global, and Medico Remedies, and Below Average at Amanta Healthcar, Haleos Labs Limi, Valiant Laborato, Transchem, and Influx Health.<BR><BR>Return Snapshot: Bafna Pharma. has a 1-year return of 135.40%, while CCME Global has the highest return at 348.05% and Valiant Laborato has the lowest at -40.70%. Bafna Pharma's return is significantly positive compared to its peers. Additionally, the six-month return is negative for Haleos Labs Limi, CCME Global, Albert David, and Medico Remedies.

Should I buy, sell or hold Bafna Pharmaceuticals Ltd?

Are Bafna Pharmaceuticals Ltd latest results good or bad?

Bafna Pharmaceuticals Ltd's latest Q3 FY26 results are concerning, showing a 30.40% decline in net profit and the lowest operating margin in four quarters at 7.97%. Despite a positive half-yearly growth, the reliance on non-operating income raises doubts about the sustainability of their earnings.

Bafna Pharmaceuticals Ltd's latest results for Q3 FY26 indicate a concerning trend. The net profit of ₹1.84 crores represents a significant decline of 30.40% compared to the previous quarter. Additionally, the operating margin has dropped to 7.97%, which is the lowest level in four quarters, raising concerns about the company's operational efficiency and sustainability of margins.<BR><BR>While the half-yearly performance showed a positive growth of 38.55% in profit after tax compared to the same period last year, the recent quarterly results suggest that the company is struggling to maintain this momentum. The heavy reliance on non-operating income, which accounted for 66.30% of profit before tax, further complicates the picture, indicating that core operations may not be generating sustainable earnings.<BR><BR>Overall, the combination of declining profits, compressed margins, and reliance on non-operating income points to significant challenges for Bafna Pharmaceuticals, leading to a more negative outlook on their latest results.

How has been the historical performance of Bafna Pharma.?

Bafna Pharma has experienced a significant decline in financial performance, with net sales dropping from INR 185.34 crore in March 2014 to INR 43.36 crore in March 2019, and consistent losses in operating profit, profit before tax, and profit after tax since 2015. The company's total assets and cash flow from operating activities have also decreased, indicating a challenging financial period.

Answer:<BR>The historical performance of Bafna Pharma has shown a declining trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Bafna Pharma's net sales have decreased significantly from INR 185.34 crore in March 2014 to INR 43.36 crore in March 2019. The total operating income followed a similar downward trajectory, dropping from INR 185.34 crore in March 2014 to INR 43.36 crore in March 2019. The company's total expenditure, excluding depreciation, also fell from INR 162.50 crore in March 2014 to INR 56.70 crore in March 2019. Operating profit (PBDIT) has been negative since March 2016, with a loss of INR 13.34 crore reported in March 2019. Profit before tax has consistently been negative since March 2015, culminating in a loss of INR 17.28 crore in March 2019. The profit after tax has also remained negative, with a loss of INR 18.35 crore in March 2019. The company's total assets decreased from INR 199.83 crore in March 2015 to INR 71.31 crore in March 2020, while total liabilities dropped from INR 199.83 crore to INR 71.31 crore in the same period. Cash flow from operating activities has been negative since March 2016, with a cash outflow of INR 34.00 crore in March 2020. Overall, Bafna Pharma's financial performance reflects a challenging period with declining revenues and increasing losses.

Is Bafna Pharma. overvalued or undervalued?

As of November 27, 2025, Bafna Pharma is considered overvalued with a valuation grade of expensive, reflected in its high PE ratio of 34.67 and EV to EBITDA of 25.19, despite a strong year-to-date return of 102.48%.

As of 27 November 2025, the valuation grade for Bafna Pharma has moved from very expensive to expensive. The company is currently considered overvalued. Key ratios include a PE ratio of 34.67, an EV to EBITDA of 25.19, and a ROE of 12.46%. <BR><BR>In comparison to peers, Sun Pharma has a higher PE ratio of 37.62 and an EV to EBITDA of 24.87, while Cipla, which is rated attractive, has a significantly lower PE of 22.67 and an EV to EBITDA of 16.04. Despite a strong year-to-date return of 102.48% compared to the Sensex's 9.70%, the high valuation ratios suggest that Bafna Pharma's stock price may not be justified at current levels.

Who are the top shareholders of the Bafna Pharma.?

The top shareholder of Bafna Pharma is Srjr Lifesciences LLP, holding 74.57%. Other notable shareholders include three foreign institutional investors with 8.53% and individual investor Alpana Mundra with 2.91%, while there are no pledged promoter holdings or mutual fund investments.

The top shareholders of Bafna Pharma include the promoters, with Srjr Lifesciences LLP holding the highest stake at 74.57%. Additionally, there are three foreign institutional investors (FIIs) who collectively hold 8.53%. On the public side, Alpana Mundra is the largest individual shareholder with a 2.91% stake, while individual investors overall account for 11.06% of the company's shares. Notably, there are no pledged promoter holdings and no mutual funds currently invested in the company.

What is the technical trend for Bafna Pharma.?

As of June 4, 2025, Bafna Pharma's technical trend is bearish across multiple time frames, with bearish signals from MACD, Bollinger Bands, and moving averages, despite a mildly bullish indication from Dow Theory.

As of 4 June 2025, the technical trend for Bafna Pharma has changed from mildly bearish to bearish. The current stance is bearish with a strong indication from multiple time frames. The MACD is bearish on both the weekly and monthly charts, and Bollinger Bands also reflect a bearish trend in the same time frames. Daily moving averages confirm a bearish outlook. The KST is bearish on both weekly and monthly levels. Although the Dow Theory shows a mildly bullish signal on the weekly chart, the overall technical indicators suggest a prevailing bearish sentiment. The stock is currently priced at 75.00, with a recent high of 75.00 and a low of 75.00 today, indicating a lack of volatility.

Has Bafna Pharma. declared dividend?

Bafna Pharmaceuticals Ltd has declared a 6% dividend, amounting to 0.6 per share, but the dividend yield is 0%. Despite the recent negative returns over shorter periods, the company has shown a significant positive return of 647.95% over the past five years.

Bafna Pharmaceuticals Ltd has declared a 6% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 6%<BR>- Amount per share: 0.6<BR>- Ex-date: 19 Sep 13<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -10.98%, the dividend return was 0%, resulting in a total return of -10.98%.<BR><BR>Over the past year, the price return was -14.66%, with a dividend return of 0%, leading to a total return of -14.66%.<BR><BR>In the 2-year period, the price return was -41.86%, the dividend return remained at 0%, culminating in a total return of -41.86%.<BR><BR>For the 3-year period, the price return was -40.07%, with no dividend return, resulting in a total return of -40.07%.<BR><BR>In the last 4 years, the price return was -46.01%, the dividend return was 0%, which resulted in a total return of -46.01%.<BR><BR>Over the 5-year period, the price return was 647.95%, with a dividend return of 0%, leading to a total return of 647.95%.<BR><BR>Overall, while Bafna Pharmaceuticals Ltd has declared a dividend, the dividend yield is 0%, indicating that the dividend has not contributed to returns in recent periods. The total returns show significant volatility, with a stark contrast between the short-term negative returns and the long-term positive return over five years.